Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with Tardive dyskinesia

Psychopharmacology

Volumn 210, Issue 3, 2010, Pages 347-354

  Souza, Renan P ^a,b   De Luca, Vincenzo ^a,b   Remington, Gary ^a,b   Lieberman, Jeffrey A ^c   Meltzer, Herbert Y ^d   Kennedy, James L ^a,b   Wong, Albert H C ^a,e  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

GFRA2; Movement disorder; Parkinson's disease; Pharmacogenetics; Tardive dyskinesia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA 2; GROWTH FACTOR RECEPTOR; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DOMINANT INHERITANCE; DRUG EXPOSURE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; AGING; ALLELES; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA;

EID: 77955471031     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1829-4     Document Type: Article

References (46)

1. Airaksinen MS, Saarma M (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3:383-394
2. Badner JA, Gershon ES (2002) Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 7:405-411
3. Barker RA (2006) Continuing trials of GDNF in Parkinson's disease. Lancet Neurol 5:285-286
4. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
5. Bespalov MM, Saarma M (2007) GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 28:68-74
6. Borrego S, Fernandez RM, Dziema H et al (2003) Investigation of germline GFRA4 mutations and evaluation of the involvement of GFRA1, GFRA2, GFRA3, and GFRA4 sequence variants in Hirschsprung disease. J Med Genet 40:e18
7. Bourgeois M (1977) Tardive Dyskinesia induced by neuroleptics: a survey of 3140 patients in a psychiatric hospital. Encephale 3:299-320 (Pubitemid 8252699)
8. Carlsson A, Carlsson ML (2008) Adaptive properties and heterogeneity of dopamine D (2) receptors-pharmacological implications. Brain Res Rev 58:374-378
9. Casey DE (2004) Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65 (Suppl 9):25-28
10. Cass WA, Manning MW (1999) GDNF protection against 6-OHDA-induced reductions in potassium-evoked overflow of striatal dopamine. J Neurosci 19:1416-1423
11. Cass WA, Peters LE (2010) Neurturin effects on nigrostriatal dopamine release and content: comparison with GDNF. Neurochem Res
12. Durrant C, Zondervan KT, Cardon LR et al (2004) Linkage disequilibrium mapping via cladistic analysis of singlenucleotide polymorphism haplotypes. Am J Hum Genet 75:35-43
13. Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H (1964) Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand 40:10-27
14. Fjord-Larsen L, Johansen JL, Kusk P et al (2005) Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol 195:49-60
15. Gauderman WJ (2002) Sample size requirements for matched casecontrol studies of gene-environment interaction. Stat Med 21:35-50
16. Gimm O, Dziema H, Brown J et al (2001) Over-representation of a germline variant in the gene encoding RET co-receptor GFRalpha-1 but not GFRalpha-2 or GFRalpha-3 in cases with sporadic medullary thyroid carcinoma. Oncogene 20:2161-2170
17. Go CL, Rosales RL, Caraos RJ, Fernandez HH (2009) The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients. Parkinsonism Relat Disord 15:655-659
18. Grondin R, Gash DM (1998) Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. J Neurol 245: P35-P42
19. Heuckeroth RO, Enomoto H, Grider JR et al (1999) Gene targeting reveals a critical role for neurturin in the development and maintenance of enteric, sensory, and parasympathetic neurons. Neuron 22:253-263
20. Hisaoka K, Nishida A, Koda T et al (2001) Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 79:25-34
21. Hong M, Mukhida K, Mendez I (2008) GDNF therapy for Parkinson's disease. Expert Rev Neurother 8:1125-1139
22. Huang RS, Duan S, Bleibel WK et al (2007) A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A 104:9758-9763
23. Hudson J, Granholm AC, Gerhardt GA et al (1995) Glial cell linederived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36:425-432
24. Kramer ER, Aron L, Ramakers GM et al (2007) Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol 5: e39
25. Lang AE, Gill S, Patel NK et al (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459-466
26. Lavedan C, Licamele L, Volpi S et al (2009) Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 14:804-819
27. Lewis CM, Levinson DF, Wise LH et al (2003) Genome scan metaanalysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 73:34-48
28. Mattson MP, Magnus T (2006) Ageing and neuronal vulnerability. Nat Rev Neurosci 7:278-294
29. Nanobashvili A, Airaksinen MS, Kokaia M et al (2000) Development and persistence of kindling epilepsy are impaired in mice lacking glial cell line-derived neurotrophic factor family receptor alpha 2. Proc Natl Acad Sci U S A 97:12312-12317
30. Ohta K, Kuno S, Inoue S et al (2010) The effect of dopamine agonists: the expression of GDNF, NGF, and BDNF in cultured mouse astrocytes. J Neurol Sci
31. Oo TF, Kholodilov N, Burke RE (2003) Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal glial cell line-derived neurotrophic factor in vivo. J Neurosci 23:5141-5148
32. Remington G (2007) Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 20:131-137
33. Rossi J, Luukko K, Poteryaev D et al (1999) Retarded growth and deficits in the enteric and parasympathetic nervous system in mice lacking GFR alpha2, a functional neurturin receptor. Neuron 22:243-252
34. Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487
35. Shao Z, Dyck LE, Wang H, Li XM (2006) Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells. J Psychiatry Neurosci 31:32-37
36. Soler RM, Dolcet X, Encinas M et al (1999) Receptors of the glial cell line-derived neurotrophic factor family of neurotrophic factors signal cell survival through the phosphatidylinositol 3-kinase pathway in spinal cord motoneurons. J Neurosci 19:9160-9169
37. Souza RP, Romano-Silva MA, Lieberman JA et al (2008) Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) 200:177-186
38. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL (2010a) Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 20:274-276
39. Souza RP, Romano-Silva MA, Lieberman JA et al (2010b) Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. J Psychiatr Res
40. Tenback DE, van Harten PN, van Os J (2009) Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a metaanalysis. Mov Disord 24:2309-2315
41. Thelma B, Srivastava V, Tiwari AK (2008) Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 9:1285-1306
42. Tsai HT, Caroff SN, Miller DD et al (2009) A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet
43. Vanhorne JB, Gimm O, Myers SM et al (2001) Cloning and characterization of the human GFRA2 locus and investigation of the gene in Hirschsprung disease. Hum Genet 108:409-415
44. Weinhold P, Wegner JT, Kane JM (1981) Familial occurrence of tardive dyskinesia. J Clin Psychiatry 42:165-166
45. Woods SW, Morgenstern H, Saksa JR et al (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry
46. Yassa R, Ananth J (1981) Familial tardive dyskinesia. Am J Psychiatry 138:1618-1619